Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Shares of NAVB opened at $0.11 on Friday. The company has a market capitalization of $3.86 million, a price-to-earnings ratio of -0.22 and a beta of 1.51. The stock has a 50 day moving average of $0.11 and a 200 day moving average of $0.22. Navidea Biopharmaceuticals has a 12 month low of $0.07 and a 12 month high of $0.71.

Get Navidea Biopharmaceuticals alerts:

Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) last issued its quarterly earnings results on Thursday, May 11th. The company reported ($0.05) EPS for the quarter.

Hedge Funds Weigh In On Navidea Biopharmaceuticals

A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. Renaissance Technologies LLC increased its stake in Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) by 264.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 238,133 shares of the company’s stock after purchasing an additional 172,800 shares during the quarter. Renaissance Technologies LLC owned about 0.74% of Navidea Biopharmaceuticals worth $62,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.00% of the company’s stock.

About Navidea Biopharmaceuticals

(Get Free Report)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Featured Articles

• Five stocks we like better than Navidea Biopharmaceuticals
• MarketBeat Week in Review – 7/10 – 7/14
• Wells Fargo’s Earnings, Why Markets Are Loving The Stock
• Citigroup Leads Banking Earnings, What’s Next?
• BlackRock Kicks Off Financials Earnings Season, Gauge To Markets
• JPMorgan Chase Is In Reversal But Don’t Chase It Higher 

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.